Introduction
Infection of cells by viruses begins with the attachment of the virus to the surface of the host cell (Dales, 1973; Lonberg-Holm & Philipson, 1974; Dimmock, 1982; Tardieu et al., 1982; Paulson, 1985; Marsh & Helenius, 1989) . Attachment is mediated by the binding of a viral attachment protein (VAP) to a molecule on the cell surface acting as a virus receptor. The VAPs are the polypeptides forming the coat of enveloped viruses and the capsid of non-enveloped viruses. The virus receptor is potentially any normal constituent comprising or associated with the host cell membrane. The attachment step of the viral infectious cycle represents an ideal target for agents that prevent infection by inhibiting the attachment of virus to the host cell receptor. In order to develop agents that prevent attachment, it is necessary to identify the binding domains of the VAP and of the virus receptor and determine how they interact at a molecular level. In recent years, several host cell receptors for viruses have been identified as well as the regions of the receptor and VAP that mediate binding. In addition, there are many examples of agents that prevent infection by targeting the recognition event between virus and cell. This review summarizes current information on the binding domains of host cell receptors and VAPs and reviews examples where this knowledge serves as a basis for the rational development of agents that block the interaction of viruses with host cell receptors.
Host cell receptors for viruses
Virus receptors and the binding domains of the receptors and VAPs are listed in Table 1 . The evidence is stronger for some of the virus-receptor interactions than for others and relatively few receptors have been identified unambiguously. However it can be expected that future research will result in revisions and additions to the list of virus receptors. In particular, techniques involving the isolation of cDNA clones encoding virus receptors, used to identify the rhinovirus and poliovirus receptors (Table  1) for example, promise to lead to the identification of many additional virus receptors. The examples in Table  1 are limited to those for which the specific identity of the host cell receptor and the binding domain of the VAP are known. For many other viruses, only the general nature of the receptors (e.g. protein) or the VAP (e.g. coat glycoprotein) is known.
Virus receptors have been defined as structures on the cell surface to which virus attachment is followed by a biologically relevant response, usually infection of the cell (Tardieu et al., 1982) .Identification of virus receptors has proved extremely difficult because virus particles can adhere to many substances, including inert materials, so it is often difficult to distinguish between non-specific binding and biologically relevant binding. Viruses may adhere to cell surfaces non-specifically through electrostatic interactions (Tardieu et al., t982) . As solutes and small particles are internalized through fluid-phase or constitutive endocytosis (Steinman et al., 1983) , it would be expected that some virus particles might be internalized through this non-specific mechanism. Specific virus receptors may be present in low numbers on the cell surface or may be labile, making identification difficult.
In addition it appears that some viruses can utilize more than one type of receptor. Finally, as discussed below, viruses may bind to intermediate molecules which in turn bind to cell surface components.
Binding of virus particles to receptors brings them in intimate physical contact with the cell surface and sets the stage for crossing the membrane barrier. Viruses then enter the cell either by direct fusion with the plasma membrane or by adsorptive or receptor-mediated endocytosis ( Fig. 1 ) (see Paulson, 1985 and Helenius, 1989 for review of entry of enveloped and non-enveloped viruses into cells). In adsorptive endocytosis, the receptor-virus complex is internalized in clathrin-coated pits and delivered to endosomes. The acidic interior of the endosome triggers a conformational change in the viral 
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Virlon Fig. 1 . Entry of enveloped viruses into cells. The virus particle bears VAPs embedded in its plasma membrane, which interact with cell surface molecules (virus receptors) attaching the virion to the cell surface. The membrane of the virion may then fuse directly with the plasma membrane releasing the genome into the cytoplasm. Alternatively the virus particle is internalized by adsorptive or receptormediated endocytosis and delivered to an endosome. The acidic pH triggers fusion of the viral membrane with the endosome membrane, liberating the genome.
fusion protein. Exposed hydrophobic sequences induce fusion of the viral membrane or virus particle with the endosome membrane allowing the viral genome to escape into the cytoplasm. Some viruses require proteolytic cleavage of a fusion protein or haemagglutination protein by a host protease before fusion can occur. This cleavage exposes a new hydrophobic N-terminal region. Similarly, direct fusion of virions with the plasma membrane releases the genome into the cytoplasm. Some viruses may utilize one of the two pathways preferentially, but many viruses have been shown to enter by both mechanisms.
Carbohydrates, lipids and proteins have been found to act as virus receptors (Table 1) . Polyoma virus and orthomyxoviruses bind to the sialyloligosaccharides of glycoproteins and glycolipids (gangliosides). Vesicular stomatitis virus recognizes phosphatidylserine and phosphatidylinositol. Most other viruses attach to proteins associated with the cell surface. Some of these proteins are members of the immunoglobulin superfamily (White & Littman, 1989) . These include the CD4 receptor which serves as the human immunodeficiency virus (HIV) receptor, intercellular adhesion molecule 1 which is the rhinovirus receptor, the receptor for poliovirus, and major histocompatibility complex (MHC) molecules which have been suggested to act as receptors for several viruses including human adenovirus, cytomegalovirus, Semliki Forest virus and lactate dehydrogenase-elevating virus. Other proposed virus receptors also function normally as receptors for hormones or neurotransmitters. These include epidermal growth factor receptor for vaccinia virus (Eppstein et al., 1985) , fl adrenergic receptor for reovirus 3 (Co et al., 1985) , and the acetylcholine receptor for rabies virus (Lentz et al., 1982) .
One of the most conclusively defined virus receptors is the CD4 molecule which serves as a receptor for HIV. The CD4 molecule is a glycoprotein of 60K present on the surface of T lymphocytes and some other cells (Sattentau & Weiss, 1988) . It is believed to function as an adhesion molecule by binding to class II MHC molecules present on B lymphocytes and antigen-presenting cells. This binding facilitates T cell activation. In order to illustrate the types of evidence necessary for the identification of a virus receptor, some of the information obtained for the HIV receptor is reviewed. First, HIV infects cells that express the CD4 molecule. These cells include T lymphocytes (Klatzmann et al., 1984a) , monocytes (Gartner et al., 1986) , epidermal Langerhan~ cells (Tschachler et al., 1987) , and cells in the brain (Maddon et al., 1986; Funke et al., 1987) . Monoclonal antibodies (MAbs) directed against the CD4 molecule block binding, syncytium formation, or infection of CD4-positive cells (Dalgleish et al., 1984; Klatzmann et al., 1984b; McDougal et al., 1986a) . Conversely HIV blocks the binding of a MAb against the CD4 molecule ( McDougal et al., 1986b) . Infection of CD4-positive cells with HIV reduces the cell surface expression of CD4 molecules (Dalgleish et al., I984) . Immunoprecipitation of infected cells with HIV antibodies precipitated a complex of the HIV envelope glycoprotein (gpl20) and the CD4 molecule (McDougal et al., 1986a) . Human cells that lack the CD4 molecule and are refractory to infection by HIV acquire the ability to bind virus and become permissive for infection following transfection with a cDNA clone encoding the CD4 protein (Maddon et al., 1986) . The tertiary structure of CD4 maintained by disulphide bonds is required for gpl20 binding (Ibegbu et al., 1989) .
Studies using truncated derivatives of CD4 have shown that a major recognition site for HIV lies within the first 106 amino acids of CD4 (Traunecker et al., 1988; Berger et al., 1988; Deen et al., 1988; Arthos et al., 1989) . This region, domain V1, has significant sequence homology with immunoglobulin light chain variable regions. Using mutational analysis, several studies have further localized the m~or HIV binding determinant to a region encompassing residues 31 to 57 (see Table 1 ). This region is homologous to the second complementaritydetermining region (CDR2) of immunoglobulin light chains.
These studies indicate strongly that the CD4 molecule is part of the receptor site for HIV. However other evidence indicates that the situation is more complicated, or that the virus can utilize alternative receptors. In cells exposed to HIV, binding of antibodies to MHC class II antigen HLA-DR is blocked and antibodies to HLA-DR block HIV binding (Mann et al., 1988) . These findings suggest that HLA-DR is involved in the receptor site for HIV. HIV can infect glioma and rhabdomyosarcoma cell lines some of which do not appear to express surface CD4 molecules . Infection of these cells is inhibited by neither soluble forms of the CD4 molecule nor anti-CD4 antibodies. These findings indicate the CD4 molecule is not required for HIV infection of these cells.
Receptors and viral tropisms
The nature, number and distribution of host cell receptors is a major determinant of the host range and tissue tropisms of viruses (Holland, 1961 ; Lonberg-Holm & Philipson, 1974; Crowell & Landau, 1979; Paulson, 1985; Mims, 1986) . For example, viruses infecting lymphocytes bind to molecules expressed on the surface of these cells. Examples of virus-lymphocyte receptor interactions are Epstein-Barr virus and the C3d receptor CR2 ofB lymphocytes (Fingeroth et al., 1984) and HIV-1 and the CD4 molecule of T lymphocytes (Dalgleish et al., 1984; Klatzmann et al., 1984b; McDougal et al., 1986b) . However, it is clear that other factors contribute to tissue tropisms. As mentioned above, HIV can infect cells which lack the CD4 molecule. In addition, HIV-I does not infect mouse cells transfected with a CD4 cDNA, although it does bind to the surface of mouse cells bearing CD4, indicating that other factors in addition to CD4 are required for infection (Maddon et al., 1986; Levy, 1988) . One such factor could be the MHC class II antigen HLA-DR which may be in close proximity to the CD4 molecule and contribute to the HIV-1 binding site (Mann et al., 1988) . In addition, many factors acting on the stages of the infectious cycle subsequent to attachment are required for virus replication, and these affect cell tropism also.
Other receptors are distributed widely among cell types or species making it difficult to understand how they alone can confer specificity. For example, poliovirus replicates in the gut and in motor neurons of primates. Its receptor has been identified as a previously unidentified member of the immunoglobulin superfamily (Mendelsohn et al., 1989) . However mRNA encoding the receptor is present in cells to which the virus does not attach and in which it does not replicate. It is possible that post-translational modifications are necessary for expression of the poliovirus receptor sites or that additional proteins interacting with the receptor are necessary for virus-binding activity (Mendelsohn et al., 1989) .
Influenza viruses bind the sialic acid (N-acetylneuraminic acid) of oligosaccharides on cell surface glycoproteins and glycolipids (Paulson, 1985) . Sialic acid binds to a pocket of conserved residues on the top of the virus haemagglutinin molecule (Weis et al., 1988) . Sialyloligosaccharide structures are distributed widely among different tissues and animal species but also are quite diverse in structure. Different strains of influenza viruses as well as other viruses binding sialic acids are able to recognize specific sialyloligosaccharide structures . Amino acid substitutions in the conserved pocket of the haemagglutinin result in changes in specificity for different sialosides . A substitution of Leu to Gln at position 226 results in a change in preferential binding specificity from NeuAcct2,6Gal linkage to NeuAcct2,3Gal. Similarly, a single amino acid change in the gpl20 of HIV causes a restriction in viral tropism (Cordonnier et al., 1989a ).
Binding to receptors through an intermediate molecule
Many viruses interact directly with a host cell receptor, whereas some viruses bind indirectly via an intermediate molecule. The best known example of this type of interaction is the enhancement of virus infection by antibodies, which has been demonstrated for several viruses (Halstead, 1988) including dengue virus (Halstead & O'Rourke, 1977) , West Nile virus (Peiris et al., 1981) , and most recently HIV (Homsy et al., 1989) . The Fc portion of anti-virus antibodies coating the virus interacts with cell surface Fc receptors, cross-linking virions to the cell surface and facilitating uptake of the virus-antibody complex. In addition, complementdependent enhancement of West Nile virus infectivity has been described in which the C3b component of complement binds complexes of virus and IgM to type 3 complement receptors of macrophages (Cardosa et al., 1986) . Similarly, polymerized serum albumin can act as an intermediate receptor for hepatitis B virus by binding to polymeric albumin receptors on hepatocytes (Machida et al., 1984) . Hepatitis B virus can also bind directly to other receptors in the membranes of hepatocytes (Pontisso et al., 1989) . f12 Microglobulin may serve as an intermediate receptor for cytomegalovirus (Grundy et al., 1987) . f12 Microglobulin coating the virus is considered to displace f12 microglobulin from the class I HLA heavy chain-fl2 microglobulin complex and bind the virus to the HLA molecule. Viruses attached to host cell receptors may be able to act as a bridge for entry by other viruses. The sialic acid residues on the envelopes of vesicular stomatitis virus and Semliki Forest virus can bind to the haemagglutinin of influenza virus present on the surface of infected cells (Fuller et al., 1985) . The utilization of intermediate receptors by viruses increases the range of susceptible cell types and complicates the strategy of preventing infection by blocking the attachment. However it has been suggested that for HIV, blocking the HIV-CD4 interaction, e.g. with soluble CD4, could be complemented with blocking the relevant Fc receptors to prevent uptake of the virus immune complexes (Homsy et al., 1989) .
Conservation of binding domains
A major advantage of intervention at the attachment stage of the viral infectious cycle is that the binding domain on the VAP is likely to be conserved among strains of virus that maintain the same tropism. This is particularly important for possible therapies in the case of viruses such as HIV-1 and influenza viruses which evade immune clearance by frequent mutation. A segment of the HIV-I gpl20 considered to interact with the CD4 molecule contains regions that are highly conserved among various HIV-1 isolates as well as in HIV-2 and simian immunodeficiency virus-1 (SIV-1) which also bind to CD4 (Lasky et al., 1987) . Also it seems likely that the binding domains on the receptor are conserved if these domains are binding sites of normal ligands. It has been reported that the region on the CD4 molecule that binds gpl20 appears to be conserved (Sattentau et al., 1986) .
The receptor-binding sites of human rhinovirus 14 (Rossmann et al., 1985) , Mengo virus (Luo et al., 1987) , and on the haemagglutinin glycoprotein of influenza virus (Weis et al., 1988) lie within a canyon, pit or pocket on the virus surface. A similar depression is present on the surface of poliovirus (Hogle et al., 1985) . Determination of the three-dimensional structure of the influenza haemagglutinin complexed with sialyllactose reveals the sialic acid filling the pocket (Weis et al., 1988) . The amino acids lining these depressions are highly conserved whereas the surrounding surface residues are variable and could represent the binding sites of neutralizing antibodies. According to the canyon hypothesis, these viruses can accept mutations in the hypervariable antibody-binding sites thereby escaping the immune response while at the same time maintaining a constant receptor-binding site which is physically inaccessible to antibodies (Rossmann & Palmenberg, 1988) . It remains to be determined whether antibodies that prevent attachment are directed to the variable regions around the canyon. Antigenic sites, identified on the basis of amino acid substitutions in different strains of influenza virus, do occur in proximity to the receptorbinding pocket of the haemagglutinin (Wiley et al., 1981) . Experimental studies on neutralization of influenza virus have shown that neutralizing monomeric IgG and IgA do not inhibit binding, and therefore act on a stage subsequent to attachment and penetration, whereas larger polymeric IgA and IgM do reduce the attachment of virus to cells (Taylor & Dimmock, 1985a, b) . Eisenlohr et al. (1987) reported that the attachment of influenza virus to antigen-presenting cells is inhibited by anti-haemagglutinin IgG. In human rhinovirus 14, neutralizing immunogenic sites correspond to hypervariable regions and are located on protrusions from the virus surface (Sherry et al., 1986) .
The canyon or pit found in other picornaviruses is absent in foot-and-mouth disease virus. The receptorbinding region is a loop projecting from the surface of the virus (Acharya et al., 1989) . This region, which contains the highly conserved arginine-glycine-aspartic acid sequence, is situated within an immunodominant hypervariable region . Thus it may not be necessary for the binding site to be inaccessible to avoid neutralization by antibodies particularly if the site is smaller than an antibody 'footprint' (Colman et al., 1983; Harrison, 1989) .
Molecular mimicry
The ability of the virus to bind to a host cell receptor may be conferred by a domain on the VAP which resembles in amino acid sequence or conformation the normal ligand of the cellular receptor. Many regions of viruses and other pathogens share amino acid similarities with normal host proteins, a phenomenon termed molecular mimicry (Damian, 1987) . It was found that of over 600 MAbs against 11 different viruses, 21 or 3.5~ reacted against normal tissues (Srinivasappa et al., 1986) . Molecular mimicry can cause autoimmune disease as a result of cross-reaction of antibodies against the virus with similar epitopes on the host ceil proteins (Oldstone, 1987) . When the virus mimics the binding domain of a ligand, the virus may have the ability to bind to the receptor for the ligands. Some examples of similarities between the VAP and physiological ligands are shown in Table 2 . Upon binding to the receptor, the virus is internalized as described earlier.
Biological effects of VAP-receptor interaction
Apart from mediating entry of virus into the cell, similarities between the VAP and normal ligands may be responsible also for certain biological effects of viruses (Dayhoff et al., 1983 ) by a single underline. Regions of greatest similarity are shown. In some instances, the similarities extend beyond these regions. See Table 1 for references.
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that are unrelated to the infectious cycle. Some of the examples of virus-receptor interactions in Table 1 may actually represent interactions of the VAP with cell surface molecules which result in biological effects but may not be followed by internalization of the virus. In some virus infections, the glycoprotein is synthesized in excess and secreted or shed extracellularly. These soluble glycoproteins may be responsible for some of the observed biological effects. Biological effects exerted by viruses during the course of infection include toxic effects on cells, activation or inactivation of the immune response, and mitogenesis. Vaccinia virus encodes a polypeptide (VGF) that is structurally similar to epidermal growth factor and transforming growth factor Reisner, 1985; King et al., 1986) . VGF has been shown to stimulate tyrosine kinase activity of epidermal growth factor receptors (King et al~, 1986) and to stimulate mitogenesis . The receptor-mediated leukaemogenesis hypothesis proposes that murine leukaemia viruses induce proliferation of lymphocytes by binding to antigenspecific receptors complementary to virus envelope gene products . Synthetic peptides of a region of rabies virus glycoprotein which is structurally similar to snake venom curaremimetic neurotoxins act as competitive antagonists of the nicotinic acetylcholine receptor and inhibit carbachol-induced sodium flux into BC3H-1 cells (Donnelly-Roberts & Lentz, 1989) . Thus soluble glycoprotein or proteolytic fragments of the glycoprotein could be responsible for some of the bizarre behavioural manifestations of this disease. The gpl20 of HIV, due to interaction with the CD4 protein, causes activation of some T cell functions and suppression of others. Binding of HIV to CD4 induces the phosphorylation of CD4, possibly mediated by protein kinase C (Fields et al., 1988) . HIV activates lymphocytes with increases of intracellular inositol triphosphate and calcium, expression of interleukin-2 receptors, and induction of a motile response (Kornfeld et al., 1988) . Gpl20 also mediates immune suppression by different mechanisms. Soluble gpl20 inhibits the binding of CD4 with class II MHC molecules of B lymphocytes (Clayton et al., 1989) and inhibits the CD4-dependent response to antigen (Diamond et al., 1988) . The MHC molecule-and gpl20-binding sites, although close or overlapping, can be separated so that it should be possible to design CD4 analogues that inhibit HIV infectivity but do not affect the immune response (Lamarre et al., 1989) . GpI20 also suppresses T cell activation and expression of cytolytic actions by binding to CD4 and renders activated CD4-positive lymphoblasts susceptible to immune cytolysis (Weinhold et al., 1989) . The receptor can be affected by antibodies against the VAP. It has been reported that antibodies to gpl20 form a trimolecular complex with gpl20 bound to CD4 and suppress the activation of T cells (Mittler & Hoffmann, 1989) . In addition, HIV has been proposed to interfere with the neurotrophic factors neuroleukin (Lee Host Cell Fig. 2 . Interaction of virus with a host cell receptor and agents interfering with the attachment step. Binding of virus to a host cell is mediated by the interaction of a VAP (forming the envelope or capsid of the virus) with receptors on the cell surface. The receptor is a normal constituent of the cell surface and may function as a receptor for a physiological ligand such as a hormone, neurotransmitter, growth factor or immunoglobulin. The ability of the virus to bind to the receptor is conferred by a portion of the VAP that mimics the normal ligand structurally or conformationally. Binding of virus to the receptors may be followed by internalization of the virus by receptormediated endocytosis or by direct fusion with the plasma membrane (see Fig. 1 ). Two groups of substances can interfere with the attachment step by blocking binding of virus to the receptor. Ligand mimics resemble the ligand and will bind to the receptor. Ligand mimics include antibodies to the binding site of the receptor, antiidiotypic antibodies against anti-ligand antibodies, natural ligands of the receptor, and designed or engineered ligand mimics such as drugs or synthetic peptides. Receptor mimics resemble the binding domain of the receptor and will bind to the VAP. Receptor mimics include antibodies against the binding domain of the ligand, anti-idiotypic antibodies against anti-receptor antibodies, soluble forms of the receptor itself, and designed receptor mimics such as synthetic peptides representing the binding domain of the receptor.
et al., 1987) and vasoactive intestinal polypeptide (Brenneman et al., 1988) by virtue of portions of the gpl20 which are structurally similar to these factors. Thus some of the neurological effects and dementia observed in patients with AIDS could be the result of inhibition of the normal neurotrophic factors.
Agents mimicking the VAP (iigand mimics)
Two general classes of agents should, in theory, prevent virus entry into ceils by blocking the attachment of virus particles to host cell receptors (Fig. 2) . The first group of agents resembles structurally or conformationally the binding domain on the VAP and should competitively inhibit binding of the VAP to the cellular receptor. Substances mimicking the binding domain of the VAP are: antibodies directed against the binding site of the receptor; anti-idiotypic antibodies against antibodies to the binding domain of the VAP; natural ligands of the binding site of the receptor; designed ligand mimics. The latter include synthetic peptides of the VAP or designed drugs that mimic the VAP. All four of these types of agents have been shown to inhibit virus binding or infectivity.
Antibodies
As described above, antibodies against the CD4 molecule inhibit HIV binding and infectivity. Some of the antibodies that block HIV infection are directed against the gpl20-binding site on CD4 (Landau et al., 1988; Mizukami et al., 1988) . Other examples are the inhibition of poliovirus (Minor et al., 1984) and rhinovirus (Colonno et al., 1986 ) attachment by anti-receptor MAbs.
Anti-idiotypic antibodies
Binding of reovirus type 3 to its receptor is blocked by an anti-idiotypic MAb directed against an idiotypic determinant on a MAb directed against reovirus haemagglutinin (Kauffman et al., 1983) . As described below, this antibody was used to model a peptide resembling the ligand.
Natural ligands
Ligands mimicked by the virus which have been reported to inhibit infection of cultured cells are abungarotoxin in the case of rabies virus (Lentz et al., 1982; Tsiang et al., 1986) and epidermal growth factor in the case of vaccinia virus (Eppstein et al., 1985) . Natural ligands may have limited usefulness as therapeutic agents because they exert toxic or biological effects through their interaction with the receptor.
Designed ligand mimics
Synthetic peptides of the binding domains of the VAP (ligand mimics) inhibit the binding of vaccinia virus (Eppstein et al., 1985) , HIV (Pert et al., 1986) , foot-andmouth disease virus and Epstein-Barr virus (Nemerow et al., 1989) to their receptors. A gpl20 octapeptide (peptide T) inhibited HIV infection of human T cells in vitro (Pert et al., 1986) . In an initial trial, peptide T was reported to result in an improvement in AIDS patients (Bridge et al., 1989 ).
An important recent finding is the demonstration that biologically active peptides can be modelled, based on the structure of the hypervariable regions of antibodies . It was found that there is an amino acid similarity between residues 317 to 332 of the reovirus haemagglutinin and a combined determinant composed of the heavy and light chain second complementarity-determining regions of the anti-idiotypic antibody described above. A synthetic peptide of this region inhibited the interaction of both the antibody and reovirus type 3 with the reovirus receptor, indicating that the peptide interacts with the receptor. The peptide also exerted biological effects similar to those exerted by reovirus type 3.
Synthetic peptides have been used also to inhibit the interaction of viral fusion proteins with the plasma membrane. Oligopeptides resembling the N-terminal regions, generated by proteolytic cleavage, of the paramyxovirus F1 polypeptide and myxovirus HAz polypeptide, inhibited cell fusion and infectivity (Richardson et al., 1980) . These peptides exerted their effects on cells and not virus suggesting they might inhibit membrane-fusing activity by competing with the fusion proteins for a membrane 'receptor' site (Richardson & Choppin, 1983) .
Agents mimicking the receptor (receptor mimics)
The second group of agents that should prevent attachment of virus to host cell receptors are agents resembling the binding domain on the receptor to which the VAP binds (Fig. 2) . This group of agents includes: antibodies directed against the binding domain of the ligand; anti-idiotypic antibodies directed against antibodies to the binding site on the receptor; the receptor itself; designed receptor mimics (also referred to as molecular decoys by Gershoni & Aronheim, 1988) . The latter could be synthetic peptides of the binding domain of the receptor. Again, there are many examples of the potential effectiveness of all four types of agents, some of which are mentioned here. An additional mechanism by which agents can inhibit attachment is induction of conformational changes in the binding domain of the VAP. It has been shown that agents called WIN compounds inhibit rhinovirus binding by causing conformational changes in the canyon floor (Pevear et al., 1989) .
Antibodies
Antibodies against the region of the viral coat protein thought to be involved in binding to the receptor have been shown to block the attachment of virus. There are many other examples of antibodies directed against components of the virus capsid or envelope which inhibit adsorption of virus to cells, but the precise locations of their epitopes have not been determined. Antibodies to the binding domain of the VAP have been raised by immunization with synthetic peptides. Immunization of chimpanzees with a synthetic peptide comprising a portion of the preS2 region of the envelope protein of hepatitis B virus protected animals from hepatitis B virus (Itoh et al., 1986) . The preS2 sequence serves as the receptor for polymerized serum albumin (Pontisso et al., 1989) . Immunization of animals with synthetic peptides corresponding to the binding region of the VP1 polypeptide (Acharya et al., 1989; Fox et al., 1989 ) of foot-and-mouth disease virus resulted in the production of neutralizing antibody (Bittle et al., 1982) . Immunization of cattle with the peptide protected them against disease following inoculation with infectious virus (DiMarchi et al., 1986) . The antibodies to this region blocked the attachment of virus to cells . Antibodies against a putative binding domain of HIV gpl20 blocked the interaction of gpl20 with the CD4 molecule (Lasky et al., 1987 ; Dowbenko et al., 1988; Sun et al., 1989) . Antibodies against synthetic peptides of the proposed capsid binding sites of human rhinovirus bound to the capsid proteins and had neutralizing activity (McCray & Werner, 1987) . These studies demonstrate the potential usefulness of synthetic peptides representing the binding domains of the VAP as immunogenic agents in the development of safe and specific subunit vaccines. On the other hand, in most cases the antibodies raised against VAP peptides have very low neutralizing titres (Palmenberg, 1987) .
Antibodies that inhibit virus attachment do not have to be directed precisely against the receptor-binding region of the VAP. In the case of rhinovirus (Rossmann et al., 1985) and influenza virus (Weis et al., 1988 ) the variable antigenic sites surround the recessed receptorbinding site. Thus, antibodies binding to the antigenic sites would block binding to the receptor by steric hindrance.
Anti-idiotypic antibodies
An anti-idiotypic MAb generated against a MAb specific for the CD4 molecule mimicked the CD4 molecule and bound to the HIV glycoprotein (Chanh et al., 1987) . Also the antibody partially neutralized HIV infection of T cells in vitro. This approach in which antiidiotypic antibodies are elicited by immunization with antibodies directed against the binding site of the receptor has the advantage that it is not necessary to expose the host to virus.
Receptors
It has been shown that soluble, secreted forms of the CD4 molecule neutralize infectivity of HIV in vitro Fisher et al., 1988; Hussey et al., 1988; Deen et al., 1988; Traunecker et al., 1988) . The whole receptor is not essential, since fragments of the CD4 molecule containing the N-terminal immunoglobulin-like domains of CD4 were also effective (Berger et al., 1988; Traunecker et al., 1988; Arthos et al., 1989; Chao et al., 1989) .
Designed receptor mimics
Agents that contain the binding site of the receptor have been shown to have anti-viral activity. In the case of influenza virus, the ability of glycoproteins to inhibit haemagglutination was related to the sialic acid content of the glycoproteins (Springer et al., 1969) . A number of monovalent sialosides were tested for their ability to inhibit influenza virus adsorption to erythrocytes (Pritchett et al., 1987) . The most effective sialic acid derivatives were NeuAc~CH 3 (0~-methyl-N-acetylneuraminic acid) and NeuAc0~CvH7. Sialyloligosaccharide sequences were also tested. The most effective contained the NeuAcct2,6GlcNAc and NeuAc~2,6Gal linkages, in accordance with the receptor specificity of the influenza strain used. It should be noted that the sialosides were effective at millimolar concentrations which may limit their usefulness as therapeutic agents. Synthetic peptides of CD4 residues 25 to 58 (Jameson et al., 1988) and a benzylated 83 to 94 peptide (Lifson et al., 1988) inhibited H/V-l-induced cell fusion specifically.
Applications
Based on these examples, receptor mimics may represent useful anti-viral agents (Rossmann, 1988) . By binding to the conserved binding domains of the VAP these agents would be effective against different strains of virus. Receptor mimics could suppress or delay infection sufficiently long for the normal defensive mechanisms to clear the virus. The virus-receptor complex could be degraded or cleared from the body by normal mechanisms. These agents can be produced in large quantities by recombinant DNA techniques or by chemical synthesis. It is also possible that they can be designed or engineered to bind with even higher affinity than the native receptor and to avoid adverse effects. Potential disadvantages of receptor mimics is that they could elicit an autoimmune response or bind the natural ligand of the receptor thereby interfering with a normal physiological process. In addition they could be rapidly degraded in the body. In order to overcome this difficulty with the CD4 molecule, Capon et al. (1989) produced hybrid CD4-immunoglobulin molecules (immunoadhesins) composed of the CD4 binding domain for gpl20 and the lgG 1 heavy chain constant region. The hybrid molecules bound gpl20 and blocked infection of T cells and monocytes by HIV-1. Significantly the immunoadhesins, unlike soluble CD4 alone, showed the long half-life characteristics of antibodies in vivo. Traunecker et al. (1989) produced a CD4-IgM chimera which was highly effective in the syncytium inhibition assay and which retained effector functions including the binding of Fc receptors and the first component of the complement cascade.
Another application of receptor mimics is to utilize them to target toxic agents to infected cells. The first 178 amino acids of CD4 linked to the active regions of Pseudomonas exotoxin A (Chaudhary et al., 1988) and soluble CD4 conjugated to the active subunit of the toxin ricin (Till et al., 1988) killed HIV-infected cells. Because CD4 is believed to interact with MHC class II molecules, the CD4-toxin hybrids could interfere with functions mediated by MHC class II molecules. However, in both cases the hybrids did not affect cells expressing MHC class II antigens.
Condudon
The initial stage in the viral infectious cycle is the attachment of the virus particle to the host cell membrane. Attachment is mediated by the interaction of a viral surface protein, the VAP, with a normal component of the plasma membrane, of either protein, carbohydrate or lipid, which acts as a virus receptor. Information is accumulating rapidly not only on the nature of the VAPs and of viral receptors but also on the specific domains involved in binding. This knowledge is allowing the development of molecular models for the virus-host cell interaction. Such models permit the rational design of agents which might be effective in preventing virus infection by blocking the attachment stage of the infectious cycle. One group of agents (ligand mimics) will resemble, chemically or structurally, the binding domain of the ligand (in this case the VAP) and competitively inhibit binding of virus to the receptor. The second group of agents will resemble the binding domain of the receptor (receptor mimics) and prevent binding of virus with the host cell by attaching to the binding domain of the VAP. The author's research is supported by grants NS 21896 from the National Institutes of Health and BNS 88-05780 from the National Science Foundation.
Note added inproof. The major cell surface receptors for simian virus 40, a polyomavirus, have been reported to be class I MHC antigens (Attwood & Norkin, 1989) . The minimal receptor determinant for reovirus type 3 has been identified as the ct-anomeric form of sialic acid (Paul et al., 1989) . Sialic acid also serves as a receptor for simian and bovine rotaviruses, also of the family Reoviridae (Fukudome et al., 1989) . Monoclonal antibodies against residues 190 to 203 of the rabies virus glycoprotein inhibited binding of the rabies virus glycoprotein and ~-bungarotoxin to the nicotinic acetylcholine receptor, indicating this region of the glycoprotein mediates binding of the virus to the receptor (Bracciet al., 1988) . Deletions in four highly conserved agions (residues 82 to 95, 386 to 389, 424 to 432 and 487 to 499) of the gpl20 protein of HIV-1 (BRU strain) drastically reduced binding of HIV-1 to the CD4 antigen (Cordonnier et al., 1989b) . I apologize to those whose work I was unable to cite or of which I was unaware. I would appreciate hearing of additional information, particularly of the type summarized in Table 1 , on virus receptors and attachment proteins.
